Accent Microcell Peer Comparison
NSE: ACCENTMIC
₹605.85
As on 28-Aug-2026IST
Market cap
₹1,453 Cr
Revenue (TTM)
₹349 Cr
P/E Ratio
33.1
P/B Ratio
5.3
Div. Yield
0.2 %
| Accent Microcell | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
1,453 | 32,104 | 29,892 | 29,103 | 26,871 |
Revenue (₹ Cr) |
349 | 3,564 | 1,936 | 9,205 | 1,462 |
Net Profit (₹ Cr) |
43.86 | 414.00 | 288.22 | -371.81 | 387.35 |
Net Margin (%) |
12.33 | 11.23 | 14.79 | -3.93 | 26.01 |
RoE (%) |
18.65 | 8.38 | 29.77 | -3.85 | 25.18 |
Price to Earnings |
33.14 | 78.49 | 103.71 | -- | 69.57 |
Price-To-Book |
5.28 | 6.38 | 22.27 | 3.64 | 15.55 |
Income Statement (₹ Cr)
| Accent Microcell | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Operating Revenue
|
349.03 | 3,373.00 | 1,753.96 | 8,869.08 | -- |
|
Total Income
|
355.80 | 3,510.00 | 1,762.66 | 9,111.51 | -- |
|
Total Expenditure
|
292.34 | 2,747.00 | 1,354.69 | 7,976.59 | -- |
|
EBITDA
|
56.69 | 626.00 | 399.26 | 892.49 | -- |
|
Depreciation
|
4.66 | 227.00 | 45.26 | 831.24 | -- |
|
EBIT
|
52.04 | 399.00 | 354.00 | 61.25 | -- |
|
Interest
|
0.54 | 213.00 | 42.17 | 340.80 | -- |
|
Other Income
|
6.77 | 137.00 | 8.70 | 242.43 | -- |
|
Exceptional Items
|
-- | -85.00 | -- | -196.14 | -- |
|
Profit before Tax
|
58.26 | 238.00 | 320.53 | -176.06 | -- |
|
Provision for Tax
|
14.40 | 39.00 | 73.80 | 149.88 | -- |
|
Profit after Tax
|
43.86 | 199.00 | 246.74 | -325.94 | -- |
Liabilities (₹ Cr)
| Accent Microcell | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
275.48 | 4,940.00 | 1,288.82 | 8,162.62 | -- |
|
Minority Interest
|
-- | 341.00 | 0.00 | -- | -- |
|
Non-Current Liabilities
|
2.55 | 1,235.00 | 189.02 | 4,529.41 | -- |
|
Current Liabilities
|
56.33 | 1,622.00 | 835.87 | 4,874.74 | -- |
|
Total Liabilities
|
334.50 | 8,578.00 | 2,326.71 | 17,723.32 | -- |
Assets (₹ Cr)
| Accent Microcell | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
166.64 | 5,441.00 | 631.90 | 10,258.66 | -- |
|
Current Assets
|
167.73 | 2,606.00 | 1,681.81 | 7,308.11 | -- |
|
Total Assets
|
334.50 | 8,578.00 | 2,326.71 | 17,723.32 | -- |
|
Total Debt*
|
0.88 | 2,125.00 | 259.37 | 5,495.48 | -- |
|
Net Current Assets
|
111.40 | 984.00 | 845.94 | 2,433.37 | -- |
|
Contingent Liabilities
|
19.87 | 768.26 | 19.09 | 95.72 | -- |
Cashflow (₹ Cr)
| Accent Microcell | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
18.64 | 390.00 | 205.05 | 1,652.60 | -- |
|
Cash Flow from Investing Activities
|
-48.88 | -241.00 | -409.72 | -826.03 | -- |
|
Cash from Financing Activities
|
35.75 | -54.00 | 283.07 | -38.98 | -- |
|
Net Cash Inflow / Outflow
|
5.51 | 95.00 | 78.39 | 787.59 | -- |
Ratios
Profitability Ratios
| Accent Microcell | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
ROCE (%)
|
24.88 | 6.79 | 29.22 | 1.24 | -- |
|
ROE (%)
|
18.65 | 4.29 | 27.84 | -4.04 | -- |
|
ROA (%)
|
15.01 | 2.53 | 13.11 | -1.98 | -- |
|
EBIT Margin (%)
|
18.18 | 22.62 | 23.26 | 12.80 | -- |
|
Net Margin (%)
|
12.33 | 5.67 | 14.00 | -3.58 | -- |
|
Cash Profit Margin (%)
|
13.90 | 10.98 | 7.71 | 4.80 | -- |
Growth Ratios
| Accent Microcell | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
31.92 | 11.99 | 36.57 | -3.08 | -- |
|
EBIT Growth (%)
|
31.34 | 67.69 | 52.29 | -28.15 | -- |
|
Net Profit Growth (%)
|
32.65 | 449.12 | 83.64 | -457.66 | -- |
|
EPS Growth (%)
|
16.36 | 553.20 | 71.44 | -456.91 | -- |
|
Book Value Growth (%)
|
41.42 | 13.47 | 144.31 | 0.33 | -- |
Valuation Ratios
| Accent Microcell | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Price / Earnings
|
19.43 | 89.54 | 51.69 | 0.00 | -- |
|
Price / Book Value
|
3.09 | 3.87 | 10.14 | 2.24 | -- |
|
Dividend Yield (%)
|
0.28 | 0.00 | 0.19 | 0.00 | -- |
|
EV/EBITDA
|
13.13 | 27.45 | 31.05 | 19.72 | -- |
|
Market Cap (₹ Cr)
|
852.20 | 19,071.62 | 12,753.19 | 18,108.89 | -- |
Solvency Ratios
| Accent Microcell | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.43 | 0.21 | 0.68 | -- |
|
Short term debt to equity ratio
|
-- | 0.09 | 0.05 | 0.09 | -- |
|
Current Ratio
|
2.98 | 1.61 | 2.01 | 1.50 | -- |
|
Quick Ratio
|
2.40 | 1.06 | 1.14 | 0.87 | -- |
|
Interest Coverage
|
108.87 | 2.12 | 8.60 | 0.48 | -- |
Operating Efficiency Ratios
| Accent Microcell | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
26.16 | 17.43 | 29.00 | 24.33 | -- |
|
Asset Turnover
|
1.19 | 0.49 | 2.01 | 0.64 | -- |
|
Receivable days
|
81.66 | 58.75 | 40.13 | 78.20 | -- |
|
Inventory Days
|
34.53 | 75.82 | 60.29 | 93.30 | -- |
|
Payable days
|
32.26 | 186.21 | 232.47 | 226.14 | -- |
|
Cash Conversion Cycle
|
83.93 | -51.64 | -132.04 | -54.64 | -- |